New hope for Hard-to-Treat cancers: early trial of IL-22BP begins
NCT ID NCT07040943
First seen Apr 23, 2026 · Last updated May 20, 2026 · Updated 4 times
Summary
This early-stage trial tests a new drug called IL-22BP in about 6 adults with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors. The study is for people aged 18 to 70 with good daily function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MALIGNANT SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Radiation Oncology
RECRUITINGChengdu, Sichuan, 610000, China
Contact
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610000, China
Contact
Conditions
Explore the condition pages connected to this study.